SS
SPRY icon

SBI Securities’s ARS Pharmaceuticals SPRY Stock Holding History

SBI Securities’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9K Buy
2,115
+1,465
+225% +$12.6K ﹤0.01% 1607
2026
Q1 		$5.22K Sell
650
-99
-13% -$949 ﹤0.01% 2010
2025
Q4 		$8.73K Buy
749
+51
+7% +$496 ﹤0.01% 1777
2025
Q3 		$7.01K Buy
698
+48
+7% +$689 ﹤0.01% 1915
2025
Q2 		$11.3K Sell
650
-7
-1% -$101 ﹤0.01% 1649
2025
Q1 		$8.27K Sell
657
-15,896
-96% -$191K ﹤0.01% 1683
2024
Q4 		$175K Buy
+16,553
New +$232K 0.01% 583

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

SBI Securities's SPRY Position: Q2 2026 in Review

SBI Securities increased its ARS Pharmaceuticals (SPRY) stake by 225% in Q2 2026, buying an estimated $12.6K and bringing the position to 2,115 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

SBI Securities first reported a position in SPRY in Q4 2024 and has held it in 7 quarters since. The position peaked at $175K in Q4 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • SBI Securities held 2,115 shares of ARS Pharmaceuticals worth $16.9K as of Q2 2026.
  • SBI Securities bought 1,465 ARS Pharmaceuticals shares in Q2 2026, an estimated $12.6K.
  • ARS Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1607 holding.
  • SBI Securities first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's ARS Pharmaceuticals position peaked at $175K in Q4 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.